287,686 Shares in Repligen Corporation $RGEN Bought by Blue Whale Capital LLP

Blue Whale Capital LLP acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 287,686 shares of the biotechnology company's stock, valued at approximately $35,782,000. Repligen comprises about 2.3% of Blue Whale Capital LLP's investment portfolio, making the stock its 16th largest holding. Blue Whale Capital LLP owned approximately 0.51% of Repligen at the end of the most recent reporting period.

• Why Medical Products Maker Repligen May Be A Potential Buy

Other large investors also recently modified their holdings of the company. Twin Tree Management LP acquired a new stake in shares of Repligen in the first quarter worth $29,000. Hantz Financial Services Inc. grew its position in Repligen by 2,663.6% in the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 293 shares during the last quarter. Center for Financial Planning Inc. raised its position in shares of Repligen by 34.2% during the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company's stock valued at $61,000 after buying an additional 126 shares during the last quarter. AlphaQuest LLC acquired a new stake in Repligen during the second quarter worth about $104,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Repligen during the first quarter worth about $132,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of research reports. HSBC started coverage on Repligen in a research report on Wednesday, October 1st. They issued a "buy" rating and a $150.00 price objective for the company. Wells Fargo & Company dropped their price objective on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday, July 30th. Canaccord Genuity Group lifted their price objective on Repligen from $150.00 to $165.00 and gave the company a "hold" rating in a report on Wednesday, October 29th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $205.00 price target on shares of Repligen in a report on Tuesday, September 2nd. Finally, Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $173.85.

Get Our Latest Stock Analysis on Repligen

Repligen Stock Performance

Shares of NASDAQ:RGEN opened at $171.76 on Wednesday. The company's 50 day simple moving average is $146.77 and its 200 day simple moving average is $130.95. The stock has a market capitalization of $9.67 billion, a price-to-earnings ratio of 8,592.30, a price-to-earnings-growth ratio of 3.32 and a beta of 1.15. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, topping analysts' consensus estimates of $0.42 by $0.04. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The business had revenue of $188.81 million for the quarter, compared to analyst estimates of $181.23 million. During the same quarter in the previous year, the company posted $0.43 EPS. Repligen's quarterly revenue was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, research analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO James Bylund sold 2,191 shares of the business's stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the transaction, the chief operating officer owned 21,520 shares in the company, valued at $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Anthony Hunt sold 25,000 shares of the company's stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $156.88, for a total transaction of $3,922,000.00. Following the sale, the director directly owned 100,743 shares in the company, valued at $15,804,561.84. This trade represents a 19.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 49,382 shares of company stock worth $7,676,802 in the last 90 days. Corporate insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

• Five stocks we like better than Repligen
• What is the S&P 500 and How It is Distinct from Other Indexes
• Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
• 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
• From Science Project to Solvent: WeRide’s 761% Revenue Surge
• Diversification Can Smooth Returns And Mitigate Portfolio Risk
• Will the S&P 500 Rally in December? These 3 Signals Point to a Big Move Ahead

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Repligen Right Now?

Before you consider Repligen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.

While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here